Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
| Revenue (Most Recent Fiscal Year) | $68.73B |
| Net Income (Most Recent Fiscal Year) | $9.40B |
| PE Ratio (Current Year Earnings Estimate) | 13.56 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 2.52 |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.14 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.99 |
| Pre-Tax Margin (Trailing 12 Months) | 18.90% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 1.48 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.20 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.85 |
| Inventory Turnover (Trailing 12 Months) | 2.12 |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.44 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $2.67 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 6.38B |
| Free Float | -- |
| Market Capitalization | $252.09B |
| Average Volume (Last 20 Days) | 1.91M |
| Beta (Past 60 Months) | 0.46 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.87 |
| Dividend Yield (Based on Last Quarter) | 2.21% |